ASH: KOS-953
Kosan Biosciences Incorporated today reported interim results from two clinical trials of KOS-953, Kosan’s proprietary formulation of the Hsp90 inhibitor 17-AAG, in two oral presentations at the 47th Annual Meeting of the American Society of Hematology. Data from a Phase I single-agent clinical trial and a Phase Ib combination trial of KOS-953 co-administered with bortezomib (Velcade®) demonstrated early signs of anticancer activity and tolerability in patients with relapsed-refractory multiple myeloma.
KOS-953 is a novel formulation of 17-AAG, an Hsp90 inhibitor. In vitro and in vivo studies showed that inhibition of Hsp90 by KOS-953 leads to protein degradation and apoptosis of multiple myeloma cells. By blocking Hsp90 function, KOS-953 markedly enhances the sensitivity of multiple myeloma cells to bortezomib (Mitsiades et al 2005, Blood Epub 18 October 2005).
Source: www.kosan.com
KOS-953 is a novel formulation of 17-AAG, an Hsp90 inhibitor. In vitro and in vivo studies showed that inhibition of Hsp90 by KOS-953 leads to protein degradation and apoptosis of multiple myeloma cells. By blocking Hsp90 function, KOS-953 markedly enhances the sensitivity of multiple myeloma cells to bortezomib (Mitsiades et al 2005, Blood Epub 18 October 2005).
Source: www.kosan.com
posted by gwg at 8:44 PM
0 Comments:
Post a Comment
<< Home